Zenith Capital Corp. (ZHCLF)
USD 0.0
(-99.9%)
USD 0.0
(-99.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.94 Million USD | 20.52% |
| 2022 | -11.25 Million USD | -152407.45% |
| 2021 | -7378.00 USD | -8.9% |
| 2020 | -6775.00 USD | 27.59% |
| 2019 | -9357.00 USD | 16.14% |
| 2018 | -11.15 Thousand USD | 99.88% |
| 2017 | -9.54 Million USD | -20.18% |
| 2016 | -7.93 Million USD | 5.38% |
| 2015 | -8.38 Million USD | 32.09% |
| 2014 | -12.35 Million USD | 24.6% |
| 2013 | -16.38 Million USD | -54.23% |
| 2012 | -10.62 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.38 Million USD | -18.0% |
| 2023 Q4 | -1.17 Million USD | 39.02% |
| 2023 Q2 | -2.68 Million USD | 10.82% |
| 2023 Q1 | -3.01 Million USD | 51.91% |
| 2023 Q3 | -1.92 Million USD | 28.5% |
| 2022 Q3 | -1496.00 USD | 31.63% |
| 2022 Q1 | -1212.00 USD | 99.92% |
| 2022 FY | -11.16 Million USD | -151214.72% |
| 2022 Q2 | -2188.00 USD | -80.53% |
| 2022 Q4 | -6.26 Million USD | -418883.96% |
| 2021 Q4 | -1.49 Million USD | 20.74% |
| 2021 Q1 | -2.08 Million USD | -24.21% |
| 2021 Q2 | -1.92 Million USD | 8.05% |
| 2021 Q3 | -1.88 Million USD | 2.08% |
| 2021 FY | -7378.00 USD | -8.9% |
| 2020 Q2 | -1.77 Million USD | -11.67% |
| 2020 FY | -6775.00 USD | 27.59% |
| 2020 Q3 | -1.73 Million USD | 1.75% |
| 2020 Q4 | -1.68 Million USD | 3.34% |
| 2020 Q1 | -1.58 Million USD | 27.63% |
| 2019 Q1 | -2.54 Million USD | 36.49% |
| 2019 FY | -9357.00 USD | 16.14% |
| 2019 Q4 | -2.19 Million USD | 23.69% |
| 2019 Q3 | -2.87 Million USD | -64.09% |
| 2019 Q2 | -1.74 Million USD | 31.36% |
| 2018 Q4 | -4.01 Million USD | -55.32% |
| 2018 FY | -11.15 Thousand USD | 99.88% |
| 2018 Q3 | -2.58 Million USD | -5.43% |
| 2018 Q2 | -2.45 Million USD | -15.95% |
| 2018 Q1 | -2.11 Million USD | 23.47% |
| 2017 Q2 | -1.87 Million USD | 19.27% |
| 2017 Q3 | -2.58 Million USD | -37.45% |
| 2017 Q1 | -2.32 Million USD | -0.39% |
| 2017 FY | -9.54 Million USD | -20.18% |
| 2017 Q4 | -2.76 Million USD | -7.02% |
| 2016 FY | -7.93 Million USD | 5.38% |
| 2016 Q4 | -2.31 Million USD | -27.46% |
| 2016 Q3 | -1.81 Million USD | 4.17% |
| 2016 Q2 | -1.89 Million USD | 0.68% |
| 2016 Q1 | -1.9 Million USD | 14.13% |
| 2015 FY | -8.38 Million USD | 32.09% |
| 2015 Q1 | -2.12 Million USD | 4.14% |
| 2015 Q4 | -2.22 Million USD | -25.38% |
| 2015 Q3 | -1.77 Million USD | 21.69% |
| 2015 Q2 | -2.26 Million USD | -6.39% |
| 2014 Q4 | -2.22 Million USD | 1.2% |
| 2014 Q1 | -4.3 Million USD | 8.59% |
| 2014 FY | -12.35 Million USD | 24.6% |
| 2014 Q3 | -2.24 Million USD | 29.87% |
| 2014 Q2 | -3.2 Million USD | 25.51% |
| 2013 Q2 | -3.4 Million USD | 25.99% |
| 2013 Q3 | -3.67 Million USD | -7.78% |
| 2013 Q4 | -4.7 Million USD | -28.17% |
| 2013 Q1 | -4.6 Million USD | -41.95% |
| 2013 FY | -16.38 Million USD | -54.23% |
| 2012 FY | -10.62 Million USD | 0.0% |
| 2012 Q4 | -3.24 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -569.671% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -77.283% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 49.891% |
| Nascent Biotech, Inc. | -2.22 Million USD | -301.053% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1246.837% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 110.926% |
| Qrons Inc. | -643.67 Thousand USD | -1289.361% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2195.608% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 83.889% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2052.455% |
| Skye Bioscience, Inc. | -13.67 Million USD | 34.588% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 87.542% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 281.96% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -3316.932% |
| SQZ Biotechnologies Company | -75.82 Million USD | 88.206% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -213.734% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -482.208% |
| Mesoblast Limited | -84.14 Million USD | 89.372% |
| Marizyme, Inc. | -34.08 Million USD | 73.764% |
| Genus plc | 6.4 Million USD | 239.734% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 191.794% |
| Pharming Group N.V. | -4.87 Million USD | -83.275% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -350.194% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -860.188% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -7.102% |
| ContraFect Corporation | -56.88 Million USD | 84.28% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -96.346% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -537.879% |
| IMV Inc. | -38.67 Million USD | 76.874% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -225.101% |
| MultiCell Technologies, Inc. | -722.81 USD | -1237154.604% |
| ONE Bio Corp. | 13.68 Million USD | 165.365% |
| Accustem Sciences Inc. | -3.74 Million USD | -138.708% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 84.84% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1751.315% |
| Q BioMed Inc. | -3.44 Million USD | -159.547% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 352.627% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -240.359% |
| Biomind Labs Inc. | -1 Million USD | -785.794% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 83.732% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -208.246% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -34.521% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -379.679% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -29757.772% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 43.647% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -362.742% |
| GB Sciences, Inc. | -1.42 Million USD | -529.563% |
| Alpha Cognition Inc. | -9.7 Million USD | 7.857% |
| HST Global, Inc. | -140.9 Thousand USD | -6246.739% |
| CSL Limited | 3.7 Billion USD | 100.242% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -695.0% |
| Halberd Corporation | -75.05 Thousand USD | -11816.056% |
| Enzolytics Inc. | -2.14 Million USD | -316.186% |
| Agentix Corp. | -1.37 Million USD | -551.938% |
| Resverlogix Corp. | -12.74 Million USD | 29.853% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -182.267% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 97.896% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -756.609% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -206.325% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -466.244% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -162.645% |
| AVAX Technologies, Inc. | 6.69 Million USD | 233.62% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.849% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -51234.596% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -264.23% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -5114.287% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -346.089% |
| Kadimastem Ltd | -3.04 Million USD | -194.153% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -808.793% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -612.022% |
| BioStem Technologies, Inc. | -7.77 Million USD | -14.964% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -4827.68% |
| LadRx Corporation | -3.82 Million USD | -133.888% |
| Cell Source, Inc. | -4.32 Million USD | -106.758% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1201.841% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1201.841% |
| NovAccess Global Inc. | -2.46 Million USD | -262.54% |
| Affymax, Inc. | -15.04 Million USD | 40.562% |
| Itoco Inc. | -919.14 Thousand USD | -872.975% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -110.999% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -699.196% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1512.659% |
| CytoDyn Inc. | -18.05 Million USD | 50.476% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -35430.393% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3963.559% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1483.608% |
| SYBLEU INC | -149.18 Thousand USD | -5894.771% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -392.369% |
| International Stem Cell Corporation | -663 Thousand USD | -1248.869% |
| Bioxytran, Inc. | -3.82 Million USD | -134.101% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -16888.982% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -43867.552% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 75.341% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -452.719% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1115.354% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -187.464% |
| Neutra Corp. | -229.48 Thousand USD | -3796.97% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 49.011% |
| PureTech Health plc | -146.19 Million USD | 93.883% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 58.387% |
| IXICO plc | -1.43 Million USD | -522.338% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 5.774% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 92.658% |
| CSL Limited | 3.81 Billion USD | 100.235% |
| Cellectis S.A. | -108.85 Million USD | 91.785% |